Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan: Results of a Phase II Randomized Trial

Biology of Blood and Marrow Transplantation

Volumn 14, Issue 12, 2008, Pages 1401-1407

  Qazilbash, Muzaffar H ^a   Saliba, Rima M ^a   Nieto, Yago ^a   Parikh, Gaurav ^a   Pelosini, Matteo ^a   Khan, Fatima B ^a   Jones, Roy B ^a   Hosing, Chitra ^a   Mendoza, Floralyn ^a   Weber, Donna M ^b   Wang, Michael ^b   Popat, Uday ^a   Alousi, Amin ^a   Anderlini, Paolo ^a   Champlin, Richard E ^a   Giralt, Sergio ^a  

^a Department of Stem Cell Transplantation and Cellular Therapy ^*

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Arsenic trioxide; AutologousIntroduction; Myeloma

Indexed keywords

ACICLOVIR; ARSENIC TRIOXIDE; ASCORBIC ACID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; LEVOFLOXACIN; MELPHALAN; VINCRISTINE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER MORTALITY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FOOT EDEMA; GRAFT FAILURE; HUMAN; HYPERTENSION; INFECTION; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STEM CELL MOBILIZATION; STOMATITIS; VENOUS THROMBOEMBOLISM; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; ARSENICALS; ASCORBIC ACID; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; MYELOABLATIVE AGONISTS; OXIDES; SURVIVAL RATE; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 56549083786     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.09.019     Document Type: Article

References (41)

1. Hari P., Pasquini M.C., and Vesole D.H. Cure of multiple myeloma-more hype, less reality. Bone Marrow Transplant 37 (2006) 1-18
2. Kyle R.A., and Rajkumar S.V. Multiple myeloma. N Engl J Med 351 (2004) 1860-1873
3. Barlogie B., Jagannath S., Vesole D.H., et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 89 (1997) 789-793
4. Attal M., Harousseau J.L., Stoppa A.M., et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335 (1996) 91-97
5. Child J.A., Morgan G.J., Davies F.E., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348 (2003) 1875-1883
6. Fermand J.P., Katsahian S., Divine M., et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 23 (2005) 9227-9233
7. Blade J., Rosinol L., Sureda A., et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 106 (2005) 3755-3759
8. Fassas A., and Tricot G. Results of high-dose treatment with autologous stem cell support in patients with multiple myeloma. Semin Hematol 38 (2001) 231-242
9. Mehta J., Tricot G., Jagannath S., et al. Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft?. Bone Marrow Transplant 21 (1998) 887-892
10. Qazilbash M.H., Saliba R., De Lima M., et al. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer 106 (2006) 1084-1089
11. Badros A., Barlogie B., Siegel E., et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 114 (2001) 822-829
12. Moreau P., Facon T., Attal M., et al. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 99 (2002) 731-735
13. Badros A., Barlogie B., Siegel E., et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 114 (2001) 600-607
14. Lahuerta J.J., Martinez-Lopez J., Grande C., et al. Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma. Br J Haematol 109 (2000) 138-147
15. Anagnostopoulos A., Aleman A., Ayers G., et al. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma. Cancer 100 (2004) 2607-2612
16. Fenk R., Schneider P., Kropff M., et al. High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study. Br J Haematol 130 (2005) 588-594
17. Niu C., Yan H., Yu T., et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 94 (1999) 3315-3324
18. Soignet S.L., Frankel S.R., Douer D., et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 19 (2001) 3852-3860
19. Park W.H., Seol J.G., Kim E.S., et al. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res 60 (2000) 3065-3071
20. Perkins C., Kim C.N., Fang G., and Bhalla K.N. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L). Blood 95 (2000) 1014-1022
21. Hideshima T., Chauhan D., Richardson P., et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 277 (2002) 16639-16647
22. Bahlis N.J., McCafferty-Grad J., Jordan-McMurry I., et al. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res 8 (2002) 3658-3668
23. Campbell R.A., Sanchez E., Steinberg J.A., et al. Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid. Br J Haematol 138 (2007) 467-478
24. Munshi N.C., Tricot G., Desikan R., et al. Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia 16 (2002) 1835-1837
25. Hussein M.A., Saleh M., Ravandi F., Mason J., Rifkin R.M., and Ellison R. Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma. Br J Haematol 125 (2004) 470-476
26. Berenson J.R., Boccia R., Siegel D., et al. Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study. Br J Haematol 135 (2006) 174-183
27. Kaplan E.L., and Meier P. Nonparametric estimator from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
28. Blade J., Samson D., Reece D., et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 102 (1998) 1115-1123
29. Fox E., Razzouk B.I., Widemann B.C., et al. Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma. Blood 111 (2008) 566-573
30. Charlson M., Szatrowski T.P., Peterson J., and Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 47 (1994) 1245-1251
31. Sorror M.L., Maris M.B., Storb R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106 (2005) 2912-2919
32. Greipp P.R., San Miguel J., Durie B.G., et al. International staging system for multiple myeloma. J Clin Oncol 23 (2005) 3412-3420
33. Dimopoulos M.A., Weber D., Kantarjian H., Delasalle K.B., and Alexanian R. HyperCVAD for VAD-resistant multiple myeloma. Am J Hematol 52 (1996) 77-81
34. Palumbo A., Bringhen S., Caravita T., et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367 (2006) 825-831
35. Attal M., Harousseau J.L., Facon T., et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349 (2003) 2495-2502
36. Cavo M., Tosi P., Zamagni E., et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 25 (2007) 2434-2441
37. Attal M., Harousseau J.L., Leyvraz S., et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108 (2006) 3289-3294
38. Bruno B., Rotta M., Patriarca F., et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 356 (2007) 1110-1120
39. Barbey J.T., Pezzullo J.C., and Soignet S.L. Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol 21 (2003) 3609-3615
40. Qazilbash M.H., Saliba R.M., Aleman A., et al. Risk factors for relapse after complete remission with high-dose therapy for multiple myeloma. Leuk Lymphoma 47 (2006) 1360-1364
41. Qazilbash M.H., Saliba R.M., Hosing C., et al. Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. Bone Marrow Transplant 39 (2007) 279-283